IL2 and neoplasm: Monotherapy treatment with F16–IL2 led to a minor tumour growth retardation, compared with the control group of mice treated with saline 10% DMSO, whereas all mice in the temozolomide group exhibited a strong tumour regression by day 30 (Figure 2A).